The Molecule Behind GH001: Mebufotenin (5-MeO-DMT)
Mebufotenin—5-methoxy-N,N-dimethyltryptamine, or 5-MeO-DMT—is a potent psychoactive tryptamine that occurs naturally and can be produced synthetically. Pharmacologically, it acts as a nonselective serotonin receptor agonist, but with a notable feature that distinguishes it from many classic psychedelics: a higher affinity for the 5-HT1A receptor subtype relative to 5-HT2A. It also has a short half-life in plasma, which shapes both its psychoactive profile and its potential clinical utility.1
GH001 is a synthetic inhalation formulation of mebufotenin developed by GH Research. Rather than oral or injectable delivery, it is vaporized using a medical vaporization system and inhaled, producing a rapid onset of psychoactive effects that are unusually brief—on the order of roughly 20 to 25 minutes per dose in clinical observation. This pharmacokinetic profile is central to the formulation’s clinical rationale: a short, supervised experience that can be completed within a single visit.
Mechanistically, mebufotenin is distinct from both SSRIs and the neuroactive-steroid antidepressants. As a direct serotonin receptor agonist with preferential 5-HT1A engagement, it is thought to recruit downstream glutamatergic signaling and promote rapid neuroplasticity—pathways increasingly implicated in fast-acting antidepressant response.2 Researchers have proposed this as a potential explanation for the speed of effect observed in early studies.
It is important to be clear about its status: mebufotenin is investigational and is not approved by any regulatory authority for the treatment of depression or any other condition. GH001 has been evaluated in early-phase trials in treatment-resistant depression and—through a recently published JCP phase 2a, open-label trial—in postpartum depression.3 These are early studies, several without control arms, and their findings require confirmation in larger, randomized, placebo-controlled trials before any conclusions about clinical efficacy can be drawn.
References
- Shen HW, Jiang XL, Winter JC, et al. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010;11(8):659–666.
- Reckweg JT, Uthaug MV, Szabo A, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162(1):128–146.
- Johnson M, Aceves Baldo P, Arbe E, et al. Inhaled mebufotenin (GH001) for adult patients with postpartum depression: a phase 2a open-label clinical trial. J Clin Psychiatry. 2026;87(3):25m16284.
